REGN-COV2

REGN-COV2 is an experimental drug developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance to the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. It consists of a mixture of two monoclonal antibodies, REGN10933 and REGN10987. The combination of several antibodies is intended to prevent mutational escape.